Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2024 | Differential immune cell modulation with highly vs moderately efficacious DMTs in MS

Shane Arsenault, MD, Memorial University of Newfoundland, St. John’s, Canada, discusses his work assessing the impact of highly efficacious versus moderately efficacious therapies on plasma immune cell levels in multiple sclerosis, for which for was awarded the S. Weir Mitchell AAN Alliance Award. Using data from the HITMS database, the differential effect of moderately efficacious versus highly efficacious disease modifying therapies (DMTs) on immune cell subsets was demonstrated. Notably, much higher depletion of brain infiltrating CD19+ CXCR3+ B-cells was seen with the highly efficacious DMTs. Ongoing work aims to correlate these findings with clinical and imaging data to get a better idea of the impact of the differential immune cell subset modulation. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.